header logo image


Page 93«..1020..92939495..100110..»

Posterior vitreous detachment – Wikipedia

October 31st, 2022 1:44 am

Eye condition

Medical condition

A posterior vitreous detachment (PVD) is a condition of the eye in which the vitreous membrane separates from the retina.[1]It refers to the separation of the posterior hyaloid membrane from the retina anywhere posterior to the vitreous base (a 34mm wide attachment to the ora serrata).

The condition is common for older adults; over 75% of those over the age of 65 develop it. Although less common among people in their 40s or 50s, the condition is not rare for those individuals. Some research has found that the condition is more common among women.[2][3]

When this occurs there is a characteristic pattern of symptoms:

As a posterior vitreous detachment proceeds, adherent vitreous membrane may pull on the retina. While there are no pain fibers in the retina, vitreous traction may stimulate the retina, with resultant flashes that can look like a perfect circle.[citation needed]

If a retinal vessel is torn, the leakage of blood into the vitreous cavity is often perceived as a "shower" of floaters. Retinal vessels may tear in association with a retinal tear, or occasionally without the retina being torn.[citation needed]

A Weiss ring can sometimes be seen with ophthalmoscopy as very strong indicator that vitreous detachment has occurred. This ring can remain free-floating for years after detachment.[citation needed]

The risk of retinal detachment is the greatest in the first 6 weeks following a vitreous detachment, but can occur over 3 months after the event.

The risk of retinal tears and detachment associated with vitreous detachment is higher in patients with myopic retinal degeneration, lattice degeneration, and a familial or personal history of previous retinal tears/detachment.

The vitreous (Latin for "glassy") humor is a gel which fills the eye behind the lens. Between it and the retina is the vitreous membrane. With age the vitreous humor changes, shrinking and developing pockets of liquefaction, similar to the way a gelatin dessert shrinks and detaches from the edge of a pan. At some stage the vitreous membrane may peel away from the retina. This is usually a sudden event, but it may also occur slowly over months.

Age and refractive error play a role in determining the onset of PVD in a healthy person. PVD is rare in emmetropic people under the age of 40 years, and increases with age to 86% in the 90s. Several studies have found a broad range of incidence of PVD, from 20% of autopsy cases to 57% in a more elderly population of patients (average age was 83.4 years).[4][citation needed]

People with myopia (nearsightedness) greater than 6 diopters are at higher risk of PVD at all ages.Posterior vitreous detachment does not directly threaten vision. Even so, it is of increasing interest because the interaction between the vitreous body and the retina might play a decisive role in the development of major pathologic vitreoretinal conditions, such as epiretinal membrane.[citation needed]

PVD may also occur in cases of cataract surgery, within weeks or months of the surgery.[5]

The vitreous membrane is more firmly attached to the retina anteriorly, at a structure called the vitreous base. The membrane does not normally detach from the vitreous base, although it can be detached with extreme trauma. However, the vitreous base may have an irregular posterior edge. When the edge is irregular, the forces of the vitreous membrane peeling off the retina can become concentrated at small posterior extensions of the vitreous base. Similarly, in some people with retinal lesions such as lattice retinal degeneration or chorio-retinal scars, the vitreous membrane may be abnormally adherent to the retina. If enough traction occurs the retina may tear at these points. If there are only small point tears, these can allow glial cells to enter the vitreous humor and proliferate to create a thin epiretinal membrane that distorts vision. In more severe cases, vitreous fluid may seep under the tear, separating the retina from the back of the eye, creating a retinal detachment. Trauma can be any form from a blunt force trauma to the face such as a boxer's punch or even in some cases has been known to be from extremely vigorous coughing or blowing of the nose.

Posterior Vitreous Detachment is diagnosed via dilated eye examination. For some patients the vitreous gel is extremely clear and so it can be hard to see the PVD. In these cases, additional imaging such as Optical Coherence Tomography (OCT) or ocular ultrasound are used.[6]

Therapy is not required or indicated in posterior vitreous detachment, unless there are associated retinal tears, which need to be repaired.[7] In absence of retinal tears, the usual progress is that the vitreous humor will continue to age and liquefy and floaters will usually become less and less noticeable, and eventually most symptoms will completely disappear.[7] Prompt examination of patients experiencing vitreous humor floaters combined with expeditious treatment of any retinal tears has been suggested as the most effective means of preventing certain types of retinal detachments.[8]

More here:

Posterior vitreous detachment - Wikipedia

Read More...

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th…

October 31st, 2022 1:43 am

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia  GlobeNewswire

Continued here:
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th...

Read More...

Human Induced Pluripotent Stem Cells | ATCC

October 31st, 2022 1:42 am

Induced pluripotent stem cells (iPSCs) provide a powerful starting material to model human disease in relevant cell types. iPSCs may be generated from patients of any genetic background and possess the capacity to differentiate into almost any desired terminal cell type.

Although additional investigation is needed, researchers are beginning to focus on the potential utility of iPSCs as a tool for drug development, modeling of disease, and transplantation medicine.

Using ATCCs complete feeder- and xeno-free culture systems, researchers can generate standardized, quality controlled, and highly characterized human iPSCs lines. ATCCs iPSCs are derived by episomal, retroviral, or Sendai viral reprogramming. After gaining pluripotent status, the iPSCs may then be induced to differentiate into many cell types. These cells are valuable materials in the study of differentiation, tissue repair, disease pathogenesis, and drug discovery and development.

ATCC is a licensee of iPS Academia Japans induced pluripotent stem (iPS) cell patent portfolio and is able to bring complete cell culturing solutions for iPSCs to the research community.

ATCC iPSCs are tested for pluripotency, karyotype, growth potential, and sample purity. These authenticated materials are backed by meticulous quality control procedures, making them ideal as reference standards for physiologically relevant in vitro research.

See the original post here:
Human Induced Pluripotent Stem Cells | ATCC

Read More...

The EU Mission for the Support of Palestinian Police and Rule of Law

October 31st, 2022 1:42 am

Meet our Cybercrime Expert

Our Cybercrime Expert at EUPOL COPPS can easily be described as a smile in uniform. Esther Sense, an experienced Police Officer from Germany, holding the rank of Chief Police Investigator, joined EUPOL COPPS earlier this year and aside from her years of experience in her fields of expertise, has brought to the Mission a sunny demeanor that is a pleasure to witness daily. Esther is always ready with a kind word and a pleasant greeting, which of course, made our interview with her all the more pleasant.Tell us a little about yourself (nationality, professional background and experience and expertise)I hail from Hannover, Germany. I joined the German Police Force in 2001 and spent the first years of duty in the riot police and carrying out patrol service. In 2008 I was seconded to one of the first, newly founded Cybercrime Units in Germany, where I was part of the team building the unit from scratch.From 2013 to 2016 I worked in an IT-Development Department as a software developer for police related software.Since 2013 I have been seconded to the IT-Forensic Department. First as a regular Officer for IT-Forensics and since 2020, following a three year course at the federal CID and at university, I became a certified expert for IT-Forensic with specialisation in Linux and Car Forensics.Explain your portfolio here at EUPOL COPPSI am seconded by Germany as a Cybercrime Expert within the Police Advisory Section, and my direct counterpart is the Cybercrime Department of the Palestinian Civil Police. My portfolio seeks to support the PCP in their cybercrime endeavours, taking into account the many challenges they face, such as lack of updated equipment. I also support them on a more holistic level, including raising awareness of cybercrime within the population, a topic which is not only increasing in importance, but is one which is of direct interest to the community as a whole.What do you enjoy most about forming part of EUPOL COPPS, and about working in the Region?Working with our counterparts, as well as all Mission Members, and building friendships with such a diverse set of colleagues. Operating in a sensitive theatre such as ours, I feel very fortunate to witness different cultures in my daily life, and to call this historically special place in the world home. It is a very special experience, and one which I appreciate daily.What are the challenges you face, and how, in your view, may they be overcome?As with any other branch of the PCP, a number of political issues contribute towards the challenges faced in executing the PCPs mandate on a daily basis. The Cybercrime Department is relatively new within the PCP, founded in 2013. In keeping with their mandate, the department works on a high technical level, which is hardly understandable for non-technical persons. Since digital evidence becomes more and more important for criminal investigations, I am of the view that this department needs to increase their capacities, specially in the forensic lab, to ensure a proper and acceptable way of collecting evidence and to prevent illegal investigation methods. This has to be done not only by expanding the working environment to contend the rising numbers of cases in the Palestinian Territories, but also through constant training in investigation of digital evidence and data privacy to face the challenges that come with this very fast evolving and internationally linked field of police work.Esther, thank you so much for sharing your thoughts with the PPIO Team. Your portfolio is indeed fascinating. Despite the challenges, keep up your positive approach and we are always on hand to continue to support your highly commendable efforts!

The Community Policing Team within the Police Advisory Section here at EUPOL COPPS is composed of two very experienced colleagues, hailing from Italy and Canada respectively. Pietro Tripodi, Sostituto Commissario della Polizia di Stato holds the post of Community Policing Senior Advisor, and joined EUPOL COPPS in November 2021; whilst Sergeant Brian Lowe, Halton Regional Police Service is our Community Policing Advisor and joined the Mission in October 2021.Whilst Pietro and Brian have had very diverse careers, the evident silver thread is their years of experience (over 70 years between them) in their respective Police forces, which in turn has enabled them to not only form an excellent team, but to establish a strong and fruitful working relationship with our local counterparts, as they successfully execute their mandate within the Mission.The Community Policing Team sat down with the PPIO Team and shared their experience within EUPOL COPPS.Tell us a little about yourself (nationality, professional background and experience and expertise)Pietro: Im a Police Officer serving in the Italian State Police for the last 36 years. During my careerI have held various roles, such as armed response patrol crew and supervisor, as part of United Nation Police in Kosovo and as part of the European External Action Service as a duty officer within the Situation Room and at the Military Staff Watch Keeping Capability.Brian: I am seconded by the Royal Canadian Mounted Police to this Mission. I hold a Bachelor of Arts in Criminology, and have 35 years of policing experience and have been involved in community patrol, investigations, SWAT, Explosive Disposal, Ground Search and Rescue and Marine Patrol.My skill set includes planning, training, and operations of the various functions I have worked within.Explain your portfolio here at EUPOL COPPSPietro: Within the Mission I hold the post of Senior Police Advisor for the Community Oriented Police. In a nutshell the duties and responsibilities revolve around advising our counterparts within the Palestinian Civilian Police the best way to close the gap between the Police and society as a whole. Not an easy task given our area of operation and its challenges, but we are fortunate to enjoy an excellent working relationship with our counterparts, both centrally and throughout the districts, which in turn enables us to execute our mandate strategically and in partnership with the PCP.Brian: I am a Community Policing Advisor, and my role is to provide my PCP counterparts with strategic advice on Community Policing operations and training. As Pietro has mentioned, our working relationship with our local counterparts is a very fruitful one, and this thanks to our joint efforts in establishing a solid ground for our partnership, which goes from strength to strength.What do you enjoy most about forming part of EUPOL COPPS, and about working in the Region?Pietro: Forming part of EUPOLCOPPS is a truly rewarding experience: The Mission is formed of colleagues from all around EU as well as from Contributing Countries. That creates a very unique melting pot in term of fields of expertise and personal experience. Within the EUPOLCOPPS Police Advisory Section I have the pleasure to lead a Community Policing team in which Brian, my Canadian colleague and friend, and I ensure that our duties and responsibilities meet the requirements of our direct counterparts, and that we are able to positively contribute to the Community Policing portfolio within the PCP. The clear perception of everyday efforts by all Mission members in order to make a difference in working with our respective counterparts is what makes me proud to work in the Region.Brian: aside from our operational activities coming to fruition, what I value is the unique opportunity to meet and work with so many colleagues and local citizens from a wide variety of operational, national and cultural backgrounds.What are the challenges you face, and how, in your view, may they be overcome?Pietro: It is evident that EUPOLCOPPS operates in quite a delicate and unique right in the middle of the longest standing conflict in history. That places on our shoulders the added responsibility to understand the present situation and to do our utmost to collaborate closely with our local and international counterparts, drawing from our personal experience and expertise, thus exchanging best practices and solid policing values, the ultimate goal being the building of a modern Police Force enjoying the full trust of the society.Brian: Changing mindset in regard to adapting more community policing approaches versus the traditional reactive catching bad guys approach. While old school reaction to calls from the public still forms a significant percentage of police work, getting ahead of issues in response to community input and tackling problems in a collaborate multi-stakeholder approach is an effective tool when added to the police tool kit.Pietro and Brian, thank you! The PPIO Team is very pleased to support your endeavours. Given that your portfolio is very closely linked to ours in terms of public perception and trust in the local Authorities, we look forward to our continued partnership on our projects. Keep up the good work and the excellent teamwork!

More here:
The EU Mission for the Support of Palestinian Police and Rule of Law

Read More...

Bone Therapeutics provides Third Quarter 2022 Business Update

October 23rd, 2022 1:44 am

REGULATED INFORMATION

Here is the original post:
Bone Therapeutics provides Third Quarter 2022 Business Update

Read More...

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

October 23rd, 2022 1:44 am

Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy and Maximize Shareholder Value

Read the original here:
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Read More...

Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

October 23rd, 2022 1:44 am

Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program

Excerpt from:
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

Read More...

Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

October 23rd, 2022 1:44 am

BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today that Jerome D. Jabbour, Chief Executive Officer of Matinas BioPharma, will present at the ThinkEquity Investment Conference on Wednesday, October 26, 2022, at 10:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental Hotel in New York City.

See the article here:
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

Read More...

Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding…

October 23rd, 2022 1:44 am

Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203

Read the rest here:
Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding...

Read More...

Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility

October 23rd, 2022 1:44 am

DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that its Scorpion subsidiary plans to host the grand opening of its San Antonio facility today, October 21.

Visit link:
Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility

Read More...

Eyenovia to Present at the American Academy of Optometry’s Annual Meeting

October 23rd, 2022 1:44 am

NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced the company will present at the 2022 American Academy of Optometry’s Annual Meeting, which is taking place from October 26-29, 2022, at the at the San Diego Convention Center. Presentation details are below:

Here is the original post:
Eyenovia to Present at the American Academy of Optometry’s Annual Meeting

Read More...

Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

October 23rd, 2022 1:44 am

WESTLAKE VILLAGE, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced results of a nationwide survey of adults with seborrheic dermatitis and the healthcare providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease. The results were presented as a poster at the 2022 Fall Clinical Dermatology Conference in Las Vegas, Nevada. The online survey was conducted by The Harris Poll on behalf of Arcutis and included 300 U.S. adults (18+ years of age) who had been diagnosed with seborrheic dermatitis by a healthcare provider, of which 84% reported their current condition to be moderate or severe, and 601 licensed U.S. healthcare providers specializing in dermatology, including dermatologists, nurse practitioners (NPs), and physician assistants (PAs).

Continued here:
Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

Read More...

CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

October 23rd, 2022 1:44 am

WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.

Continue reading here:
CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

Read More...

EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd…

October 23rd, 2022 1:44 am

Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical suspension Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical suspension

See the original post here:
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd...

Read More...

EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall…

October 23rd, 2022 1:44 am

Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherence Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherence

See more here:
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall...

Read More...

Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets

October 23rd, 2022 1:44 am

HAMILTON, BERMUDA , Oct. 21, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has entered into an agreement regarding the sale of certain of its legacy assets comprised of its inner ear therapeutics research and development programs and a license to use its RNA delivery technology in certain inner ear applications to a European family office (the “Buyer”), in a multi-step process.

Excerpt from:
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets

Read More...

Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022

October 23rd, 2022 1:44 am

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster presentations at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD).

Read more from the original source:
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022

Read More...

Orion Corporation: Acquisition of Own Shares 21.10.2022

October 23rd, 2022 1:44 am

21.10.2022 at 18:30

More here:
Orion Corporation: Acquisition of Own Shares 21.10.2022

Read More...

F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with…

October 23rd, 2022 1:44 am

MANCHESTER, United Kingdom, Oct. 21, 2022 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections with a high unmet medical need, today announced at IDWeek 2022 positive data from the first 100 patients who completed study treatment in its ongoing Phase 2b open-label study (Study 32, NCT03583164) of oral olorofim as a treatment for invasive fungal infections.

Read the original post:
F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with...

Read More...

Burning Rock Announces Publication of Registration Document and Potential Direct Listing on the London Stock Exchange

October 23rd, 2022 1:44 am

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL.

Visit link:
Burning Rock Announces Publication of Registration Document and Potential Direct Listing on the London Stock Exchange

Read More...

Page 93«..1020..92939495..100110..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick